Item 8.01 Other Events.

On July 29, 2020, bluebird bio, Inc. ("bluebird") and Bristol Myers Squibb Company issued a press release announcing the resubmission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the product candidate idecabtagene vicleucel (ide-cel; bb2121) for the treatment of adult patients with multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. This submission provides further details on the Chemistry, Manufacturing and Controls (CMC) module to address the outstanding regulatory requests from the FDA in May 2020 following the original BLA submission in March 2020.

The full text of bluebird's press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
    Exhibit
      No.                                             Description
     99.1               Press release issued by bluebird bio, Inc. on July 2    9    , 2020.
      104             Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses